Stanislav M.
- Country
- Czechia
- Department
- Interni oddeleni
Research Overview
- Phase 2b/3 Randomized Double‑Blind Placebo‑Controlled Trial of Ataciguat to Slow Progression and Improve Peak VO2 in Moderate Calcific Aortic Valve Stenosis
- Comparative Phase III Trial of Ferric Derisomaltose Versus No Intravenous Iron in Iron-Deficient Patients with Symptomatic Chronic Heart Failure
- ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Data & Insights
Has run more than one trial at 68 of 551 partner sites.
Specializations
Inflammatory Bowel Disease
Clinical research activity is centered on Crohn’s disease and ulcerative colitis, with involvement in studies addressing moderately to severely active disease, clinical remission, and endoscopic response. The therapeutic scope includes both induction and maintenance strategies across chronic intestinal inflammation.
- Crohn’s disease
- Ulcerative colitis
- Clinical remission
- Endoscopic response
Additional interest extends to broader inflammatory bowel disease management, including therapies aimed at sustained disease control and mucosal healing.
Cardiovascular Disease
The investigator is active in studies of atherosclerotic cardiovascular disease, acute coronary syndrome, and established cardiovascular disease, with emphasis on prevention of major cardiovascular events and reduction of recurrent ischemic complications.
- Atherosclerotic cardiovascular disease
- Acute coronary syndrome
- Major adverse cardiovascular events
- Ischemic stroke prevention
Research also includes cardiometabolic risk reduction in patients with overweight, obesity, and elevated lipoprotein(a).
Heart Failure
Research involvement covers heart failure across multiple clinical profiles, including heart failure with reduced ejection fraction, heart failure with preserved or mildly reduced ejection fraction, and acute heart failure. The therapeutic focus includes symptom control, hospitalization reduction, and cardiovascular outcome improvement.
- Heart failure with reduced ejection fraction
- Heart failure with preserved ejection fraction
- Acute heart failure
- Cardiovascular hospitalization
Studies also address heart failure associated with systemic inflammation, obesity, and type 2 diabetes.
Thrombosis and Atrial Fibrillation
The clinical portfolio includes anticoagulation-focused research in atrial fibrillation, stroke prevention, and venous thromboembolism. This area reflects interest in reducing embolic risk and improving treatment options for thrombotic disease.
- Atrial fibrillation
- Stroke and systemic embolism prevention
- Proximal deep vein thrombosis
- Thrombolysis
Therapeutic activity also extends to patients at elevated risk for cardioembolic events and bleeding-related outcomes.
Gastrointestinal and Immune-Mediated Disorders
Additional research interests include celiac disease, erosive esophagitis due to gastroesophageal reflux disease, and immune-mediated gastrointestinal conditions. The investigator is involved in studies targeting mucosal inflammation and symptom relief across these disorders.
- Celiac disease
- Erosive esophagitis
- Gastroesophageal reflux disease
- Immune-mediated intestinal disease
These activities complement the investigator’s broader therapeutic focus on inflammatory and cardiovascular disease management at Vojenska Nemocnice Brno.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.